$NVO (-0,38 %)
$NOVO B (-0,52 %)
• Real-world study: 57% lower risk of heart attack, stroke, or death with Wegovy in obese patients w/ CV disease
• Strengthens case for broad adoption in obesity & cardiometabolic care
• Adds fuel to rivalry with Eli Lilly’s $LLY tirzepatide in weight-loss market